Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterised by unpredictable flares. Many patients with SLE are unable to achieve the recommended treatment goal of remission or the intermediate, yet still clinically beneficial, goal of Lupus Low Disease Activity State (LLD...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-08-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/9/3/e003270.full |